Literature DB >> 15014582

Divalproex Sodium Versus Valproic Acid in Hospital Treatment of Psychotic Disorders.

Thomas L. Schwartz1, Jose L. Massa, Sanjay Gupta, Sadiq Al-Samarrai, Patrick Devitt, Prakash S. Masand.   

Abstract

BACKGROUND: Approximately 50% of pharmacy prescriptions in the United States are filled with generic drugs, which have improved substantially in quality owing to increased governmental regulations. The remaining medicoeconomic question regards whether or not brand-name medications are worth the price. This study evaluates these questions for the brand-name mood stabilizer divalproex sodium and its generic counterpart, valproic acid.
METHOD: We conducted a retrospective chart review of all patients who had been taking divalproex and had been switched to valproic acid at 2 local mental health facilities in 1997. Data collected from the inpatient- and day-treatment charts for these 28 patients included dose, duration, side effects, and efficacy (determined using retrospective chart review and the Clinical Global Impressions scale [CGI]) of divalproex sodium compared with valproic acid treatment.
RESULTS: t Tests for dependent samples revealed that valproic acid was administered at higher doses than divalproex sodium, but these treatments did not differ in efficacy on the basis of CGI scores. Fisher exact test analyses revealed a trend toward more nausea with valproic acid; also, the combination of nausea, abdominal discomfort, and diarrhea occurred more often in valproic acid-treated patients. There were no differences in the discontinuation of either medicine because of side effects, or in the use of medications to treat gastrointestinal side effects. Efficacy was similar for valproic acid and divalproex sodium. There was no single, significant side effect increase for valproic acid; however, when grouped together, gastrointestinal side effects were statistically significantly increased in valproic acid-treated patients. This appears clinically insignificant because of the lack of difference in drug discontinuation rate or gastrointestinal medication use.
CONCLUSION: Given these results and that valproic acid is much less expensive than divalproex sodium, valproic acid appears to be a satisfactory substitution for divalproex sodium in the treatment of frequently hospitalized psychotic patients.

Entities:  

Year:  2000        PMID: 15014582      PMCID: PMC181204          DOI: 10.4088/pcc.v02n0203

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  4 in total

1.  Clinical and economic impact of replacing divalproex sodium with valproic acid.

Authors:  C W Cranor; W T Sawyer; S W Carson; J J Early
Journal:  Am J Health Syst Pharm       Date:  1997-08-01       Impact factor: 2.637

2.  Update on the costs of Depakote and Depakene.

Authors:  J H Feldstein; J L Curtis
Journal:  Ment Retard       Date:  1995-02

3.  Lithium: a brake in the rising cost of mental illness.

Authors:  A Reifman; R J Wyatt
Journal:  Arch Gen Psychiatry       Date:  1980-04

4.  Substitution of immediate-release valproic acid for divalproex sodium for adult psychiatric inpatients.

Authors:  J D Sherr; D L Kelly
Journal:  Psychiatr Serv       Date:  1998-10       Impact factor: 3.084

  4 in total
  2 in total

Review 1.  Switching from brand-name to generic psychotropic medications: a literature review.

Authors:  Julie Eve Desmarais; Linda Beauclair; Howard C Margolese
Journal:  CNS Neurosci Ther       Date:  2010-11-30       Impact factor: 5.243

Review 2.  Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature.

Authors:  Muhammad Atif; Muhammad Azeem; Muhammad Rehan Sarwar
Journal:  Springerplus       Date:  2016-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.